Skip to main content

Advertisement

Table 1 Clinical and demographic features of the 20 patients with diffuse systemic sclerosis

From: Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy

Sex/age (yr) Disease duration at skin biopsy (yr from RP) mRSS/score at skin biopsy Autoantibodies ILD PAH SRC RP DU
95% F 50% EOS 50% LSS   100% ANA/Scl70 25% ILD 15% PAH; 0% SCR 100% RP 30% DU
F/45 < 1 10/2 ANA/Scl-70 No No No Yes No
F/22 < 1 13/1 ANA/Scl-70 No No No Yes Yes
F/31 < 1 08/2 ANA/Scl-70 No No No Yes No
F/38 < 1 09/2 ANA/Scl-70 No Yes No Yes Yes
M/20 < 1 11/1 ANA/Scl-70 No No No Yes No
F/40 < 1 10/2 ANA/Scl-70 No No No Yes No
F/31 < 1 10/1 ANA/Scl-70 No No No Yes No
F/21 < 1 09/1 ANA/Scl-70 No No No Yes No
F/31 < 1 14/1 ANA/Scl-70 No No No Yes No
F/42 < 1 16/2 ANA/Scl-70 Yes No No Yes No
F/45 4 17/2 ANA/Scl-70 No No No Yes No
F/21 5 15/1 ANA/Scl-70 No No No Yes No
F/30 6 18/2 ANA/Scl-70 No Yes No Yes Yes
F/33 4 13/2 ANA/Scl-70 Yes No No Yes No
F/34 4 12/1 ANA/Scl-70 No No No Yes Yes
F/40 4 10/2 ANA/Scl-70 Yes Yes No Yes No
M/26 6 10/2 ANA/Scl-70 Yes No No Yes Yes
F/21 4 11/1 ANA/Scl-70 No No No Yes No
F/30 3 12/2 ANA/Scl-70 Yes No No Yes Yes
F/33 4 12/1 ANA/Scl-70 No No No Yes No
  1. Abbreviations: EOS Early-onset subset, LSS Long-standing subset, RP Raynaud’s phenomenon, mRSS Modified Rodnan skin score (maximum possible score 51), ILD Interstitial lung disease, ANA Antinuclear antibodies, Scl-70 Antitopoisomerase, PAH Pulmonary arterial hypertension, SRC Scleroderma renal crisis, DU Digital ulcers
  2. The internal organ involvement is referred to the time of biopsies